Viral Vectors-based Gene Therapy for Non-human Primates Market to Reach Over USD 92.76 Million by 2034, Expanding at a CAGR of 11.0% | Transparency Market Research

The global Viral Vectors-based Gene Therapy for Non-human Primates Market is set for rapid expansion over the next decade, driven by accelerating gene therapy research, rising investments in biotechnology, and increasing demand for reliable preclinical models. According to the latest industry assessment, the market-which stood at US$ 29.97 million in 2023-is forecast to reach more than US$ 92.76 million by 2034, expanding at a robust CAGR of 11.0% from 2024 to 2034.

Introduction: Viral vector-based gene therapy has emerged as one of the most promising areas in advanced therapeutics, offering targeted, long-lasting corrective solutions for a broad range of genetic, oncological, infectious, and neurodegenerative disorders. Non-human primates (NHPs) play a crucial role in validating these next-generation therapies due to their close physiological and genetic resemblance to humans. The increasing adoption of NHP-based studies is strengthening the viral vectors-based gene therapy ecosystem globally.

Access an overview of significant conclusions from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86394

Market Overview: The demand for viral vectors in preclinical gene therapy studies continues to surge as biotechnology companies, research institutes, and contract research organizations (CROs) actively invest in advanced therapeutic discovery. Innovations in adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral platforms are enabling more precise, efficient, and safer delivery of therapeutic genes. With ongoing scientific advancements and regulatory approvals expanding across various therapeutic areas, the viral vectors-based gene therapy for NHPs market is poised for strong and sustained growth over the next decade.

Key Drivers of Market Growth

1. Rising R&D Activities in Gene Therapy
Continuous advancements in gene therapy-including CRISPR genome editing, AAV capsid engineering, and vector optimization-are helping boost demand for robust preclinical validation frameworks involving NHPs.

2. Expansion of Therapeutic Applications
Viral vectors have moved far beyond rare genetic disorders. They are now being used for:
• Cancers
• Infectious diseases
• Neurodegenerative disorders
• Metabolic and hematological diseases
This expanding therapeutic landscape requires comprehensive preclinical studies, increasing reliance on NHP models.

3. Increased Funding and Collaborations
Growing investments from biotech firms and government agencies are accelerating viral vector production and therapy development. The launch of Vector BioMed in 2023 with US$ 15 million in funding signifies the momentum across North America.

4. High Genetic Similarity of NHPs to Humans
Species like Rhesus Macaques, sharing ~93% genetic similarity with humans, remain the preferred models for evaluating gene expression, safety profiles, and therapeutic efficacy.

Latest Market Trends

1. Dominance of AAV Vectors
Adeno-associated vectors are leading vector usage due to their high transduction efficiency, tissue specificity, and favorable safety profile. Novel AAV capsids-such as Capsida Biotherapeutics' next-generation CAP-002-are showing strong performance in NHP studies.

2. Advancements in Surgical Gene Delivery Techniques
Innovative procedures like transmastoid posterior tympanotomy are enabling safer and more targeted gene delivery into delicate organs, demonstrated in the groundbreaking Mass Eye and Ear study for inner-ear gene therapy in NHPs.

3. Growing Use of CRISPR Gene Editing
CRISPR-based viral vector delivery systems are gaining traction for:
• Functional gene repair
• Gene knock-in/knock-out
• Precision genome modulation

4. Expansion of CRO Capabilities
CROs are increasingly building advanced NHP vivariums and vector testing facilities to cater to rising demand from pharmaceutical and biotech companies.

Key Players and Industry Leaders

Competitive leadership in this market is defined by innovation in viral vector engineering, expanding therapeutic portfolios, and extensive NHP research capabilities. Major players include:
• CRISPR Therapeutics
• Voyager Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Neuracle Genetics Inc.
• Beacon Therapeutics
• REGENXBIO Inc.
• 4D Molecular Therapeutics
• Rocket Pharmaceuticals, Inc.

Each of these companies is actively developing novel vector platforms, partnering with CROs, and expanding gene therapy pipelines across rare and common diseases.

Buy this Premium Research Report and explore vital industry trends - https://www.transparencymarketresearch.com/checkout.php?rep_id=86394<ype=S

Recent Developments

• July 2024:
Abeona Therapeutics and Beacon Therapeutics began evaluating the patented AAV204 capsid for ophthalmologic gene therapies-signaling rising innovation in next-generation capsid design.

• May 2023:
REGENXBIO presented high-resolution biodistribution data at ASGCT 2023, demonstrating spatial and cellular tropism differences in NHPs following suprachoroidal administration of mixed AAV vectors.

• May 2024:
Capsida Biotherapeutics released strong preclinical results for CAP-002, showing up to 70% neuronal transduction in NHP models, marking a major milestone for neurological gene therapy.

Market Opportunities and Challenges

Opportunities
1. Growing Pipeline of Viral Vector Therapies
With 120+ viral-vector drugs in Phase II and 25 in late-stage development (as of 2022), demand for NHP validation is set to soar.

2. Expanding Application in Complex Diseases
As gene therapy extends into widespread diseases such as Alzheimer's, epilepsy, and metabolic syndromes, NHP studies will become indispensable.

3. Advances in Synthetic Biology and Vector Engineering
Next-gen AAV capsids, immune-evasive vectors, and targeted tissue-specific vectors are opening new pathways for therapeutic development.

Challenges
1. Regulatory and Ethical Concerns
Global agencies impose strict guidelines on NHP use, affecting study timelines and costs.

2. High Production and Study Costs
Viral vector manufacturing and NHP studies remain capital-intensive.

3. Biosafety Risks
Handling viral vectors requires highly controlled environments, limiting adoption by smaller labs.
Despite these challenges, the sector continues to grow due to its critical role in translating laboratory gene therapies into clinical success.

Future Outlook

The viral vectors-based gene therapy for NHPs market is expected to witness accelerated research activity, broader therapeutic applications, and improved clinical translation success rates. Key trends shaping the future include:
• Increasing integration of AI-driven vector design
• Expansion of personalized gene therapy
• Advancements in immune-tolerant viral vectors
• Growth of regional vector manufacturing hubs
North America is set to remain the leading region, supported by strong research investments, sophisticated CRO networks, and a rapidly expanding biotech sector.

Market Segmentation

By Type of Vector
• Adenoviral Vectors
• Adeno-associated Vectors (Leading Segment)
• Retroviral Vectors
• Lentiviral Vectors
• Other Vectors (Baculoviral, etc.)

By Type of Non-human Primate
• Marmosets
• Rhesus Macaques (Dominant Segment)
• Cynomolgus Monkeys
• Others (Capuchin Monkeys, Chimpanzees, etc.)

By Therapeutic Area
• Genetic Disorders
• Infectious Diseases
• Oncology
• Neurodegenerative Disorders
• Other Disorders (Hematological, Metabolic, etc.)

By End User
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

By Region
• North America (Leading Region)
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Why Buy This Report?

This comprehensive market analysis delivers:
• Detailed segmentation and revenue forecasts through 2034
• In-depth insights into R&D trends, drivers, and restraints
• Competitive landscape and profiling of leading players
• Latest advancements in vector technologies and NHP models
• Region-wise market evaluation and growth prospects
• Extensive analysis of therapeutic applications and industry pipeline
• Opportunities for investors, biotech companies, CROs, and researchers

Explore Latest Research Reports by Transparency Market Research:

Nuclear Medicine Market: https://www.transparencymarketresearch.com/nuclear-medicine-market.html

Contraceptives Market: https://www.transparencymarketresearch.com/contraceptives-market.html

Health and Wellness Market: https://www.transparencymarketresearch.com/health-and-wellness-market-report.html

Orthobiologics Market: https://www.transparencymarketresearch.com/orthobiologics-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.